trans-3-amino-1-cyclopropyl-3-(4-(10-fluoro-3-(pyridin-4-yl)-5H-benzo[e]imidazo[1,2-c][1,3]oxazin-2-yl)phenyl)cyclobutanol | 1402602-67-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: trans-3-amino-1-cyclopropyl-3-(4-(10-fluoro-3-(pyridin-4-yl)-5H-benzo[e]imidazo[1,2-c][1,3]oxazin-2-yl)phenyl)cyclobutanol
• CAS: 1402602-67-8
• 化学式: C₂₈H₂₅FN₄O₂
• 分子量: 468.531
• InChiKey: VJOYLHMPZGMJLH-QVYRIUEQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.86
• 重原子数：
  35.0
• 可旋转键数：
  4.0
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  86.19
• 氢给体数：
  2.0
• 氢受体数：
  6.0

文献信息

• NOVEL IMIDAZO-OXAZINE COMPOUND OR SALT THEREOF
  申请人：Nakamura Masayuki

  公开号：US20140005185A1

  公开（公告）日：2014-01-02

  The present invention provides an imidazooxazine compound represented by Formula (I) or a salt thereof, wherein A, B, C, and D are as defined in the specification.

  本发明提供了一种由化学式(I)表示的咪唑氧嗪化合物或其盐，其中A、B、C和D如规范中所定义。
• ANTITUMOR EFFECT POTENTIATOR COMPOSED OF IMIDAZOOXAZINE COMPOUND
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：US20150164909A1

  公开（公告）日：2015-06-18

  An antitumor effect potentiator for potentiating one or more other antitumor agents, comprising, as an active ingredient, an imidazooxazine compound represented by Formula (I), or a pharmaceutically acceptable salt thereof, wherein A, B, C, and D represent C—R 1a , C—R 1b , C—R 1c , and C—R 1d , respectively, or one or two of A, B, C, and D represent an N atom; at least two of R 1a , R 1b , R 1c , and R 1d represent hydrogen, and the other(s) represent(s) halogen; cyano; C 1-6 alkyl that may have hydroxyl group(s) as substituent(s); C 1-6 alkoxy; carbonyl having, as a substituent, hydroxyl, amino, optionally substituted mono- or di-(C 1-6 alkyl)amino, or mono- or di-(C 1-6 alkoxy)amino; or an unsaturated heterocyclic group; R 2 represents phenyl, pyridyl, or thienyl; R 3 represents hydrogen, methyl, ethyl, or cyclopropyl; and R 4 represents hydrogen or hydroxy.

  一种抗肿瘤效应增强剂，用于增强一种或多种其他抗肿瘤剂的作用，包括作为活性成分的由式（I）表示的咪唑氧噻啶化合物或其药学上可接受的盐，其中A、B、C和D分别表示C-R1a、C-R1b、C-R1c和C-R1d，或者A、B、C和D中的一个或两个表示N原子；R1a、R1b、R1c和R1d中至少两个表示氢，其他一个或多个表示卤素、氰基、C1-6烷基（可具有羟基取代基）、C1-6烷氧基、羟基、氨基、可选取代的单烷基或二烷基氨基、单烷氧基或二烷氧基氨基的卡宾基，或不饱和杂环基；R2表示苯基、吡啶基或噻吩基；R3表示氢、甲基、乙基或环丙基；R4表示氢或羟基。
• METHOD FOR PREDICTING THERAPEUTIC EFFICACY OF PI3K/AKT/mTOR INHIBITOR ON BASIS OF PHLDA1 OR PIK3C2B EXPRESSION
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP3012327A1

  公开（公告）日：2016-04-27

  An object of the present invention is to provide a chemotherapy using a PI3K/AKT/mTOR inhibitor that produces an excellent antitumor effect on a cancer patient. The present invention provides a method for predicting the therapeutic efficacy of the chemotherapy using the antitumor agent comprising a PI3K/AKT/mTOR inhibitor on a cancer patient on the basis of the expression level of PHLDA1 and/or PIK3C2B in a biological sample containing tumor cells isolated from the cancer patient.

  本发明的目的是提供一种使用PI3K/AKT/mTOR抑制剂的化疗方法，该化疗方法可对癌症患者产生极佳的抗肿瘤效果。本发明提供了一种方法，可根据从癌症患者体内分离出的含有肿瘤细胞的生物样本中 PHLDA1 和/或 PIK3C2B 的表达水平，预测使用包含 PI3K/AKT/mTOR 抑制剂的抗肿瘤剂的化疗对癌症患者的疗效。
• METHOD FOR PREDICTING THERAPEUTIC EFFICACY OF P13K/AKT/MTOR INHIBITOR ON BASIS OF PHLDA1 OR PIK3C2B EXPRESSION
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：EP3543355A1

  公开（公告）日：2019-09-25

  An object of the present invention is to provide a chemotherapy using a PI3K/AKT/mTOR inhibitor that produces an excellent antitumor effect on a cancer patient. The present invention provides a method for predicting the therapeutic efficacy of the chemotherapy using the antitumor agent comprising a PI3K/AKT/mTOR inhibitor on a cancer patient on the basis of the expression level of PHLDA1 and/or PIK3C2B in a biological sample containing tumor cells isolated from the cancer patient.

  本发明的目的是提供一种使用PI3K/AKT/mTOR抑制剂的化疗方法，该化疗方法可对癌症患者产生极佳的抗肿瘤效果。本发明提供了一种方法，可根据从癌症患者体内分离出的含有肿瘤细胞的生物样本中 PHLDA1 和/或 PIK3C2B 的表达水平，预测使用包含 PI3K/AKT/mTOR 抑制剂的抗肿瘤剂的化疗对癌症患者的疗效。
• Method for predicting therapeutic efficacy of PI3K/AKT/mTOR inhibitor on basis of PHLDA1 or PIK3C2B expression
  申请人：Taiho Pharmaceutical Co., Ltd.

  公开号：US10155990B2

  公开（公告）日：2018-12-18

  An object of the present invention is to provide a chemotherapy using a PI3K/AKT/mTOR inhibitor that produces an excellent antitumor effect on a cancer patient. The present invention provides a method for predicting the therapeutic efficacy of the chemotherapy using the antitumor agent comprising a PI3K/AKT/mTOR inhibitor on a cancer patient on the basis of the expression level of PHLDA1 and/or PIK3C2B in a biological sample containing tumor cells isolated from the cancer patient.

  本发明的目的是提供一种使用PI3K/AKT/mTOR抑制剂的化疗方法，该化疗方法可对癌症患者产生极佳的抗肿瘤效果。本发明提供了一种方法，可根据从癌症患者体内分离出的含有肿瘤细胞的生物样本中 PHLDA1 和/或 PIK3C2B 的表达水平，预测使用包含 PI3K/AKT/mTOR 抑制剂的抗肿瘤剂的化疗对癌症患者的疗效。